高级检索
当前位置: 首页 > 详情页

Transcervical endoscopic retropharyngeal lymph node (RPLN) dissection in nasopharyngeal carcinoma with RPLN recurrence.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China [2]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China [3]Department of Otorhinolaryngology, First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China [4]Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China
出处:
ISSN:

关键词: endoscopic-assisted nasopharyngeal carcinoma retropharyngeal lymph node survival transcervical approach

摘要:
Surgical access for retropharyngeal lymph node (RPLN) dissection is difficult. We aimed to examine the efficacy of transcervical endoscopic RPLN dissection (TSE-RPLND) for recurrent RPLN in nasopharyngeal carcinoma (NPC). From April 2013 to February 2019, a total of 31 patients with NPC diagnosed with RPLN recurrence underwent TSE-RPLND. The clinical characteristics, complications, and survival outcomes were retrospectively analyzed. The mean duration of surgery, quantity of bleeding and postoperative hospitalization stay were 347.9 minutes, 107.7 mL, and 8.7 days, respectively. After a median follow-up of 31.0 months, the 2-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival rates were 63.9%, 95.2%, 59.9%, and 83.3%, respectively. The long-term incidences of swallowing problems, permanent nutrient tube, tongue atrophy, and shoulder problems were 6 (19.4%), 3 (9.7%), 3 (9.7%), and 3 (9.7%), respectively. TSE-RPLND is an effective method to treat RPLN recurrence in NPC, but nerve injury-related complications should not be ignored. © 2020 Wiley Periodicals LLC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 2 区 耳鼻喉科学 3 区 外科
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 耳鼻喉科学 3 区 外科
JCR分区:
出版当年[2019]版:
Q1 OTORHINOLARYNGOLOGY Q2 SURGERY
最新[2023]版:
Q1 OTORHINOLARYNGOLOGY Q1 SURGERY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China [2]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China [2]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China [4]Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China [*1]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China [*2]Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, Guangdong 510060, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号